Speece Thorson Capital Group Inc. Has $18.41 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Speece Thorson Capital Group Inc. boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.9% during the second quarter, Holdings Channel reports. The fund owned 201,810 shares of the medical equipment provider’s stock after acquiring an additional 23,049 shares during the period. Zimmer Biomet comprises 3.7% of Speece Thorson Capital Group Inc.’s holdings, making the stock its 6th biggest holding. Speece Thorson Capital Group Inc.’s holdings in Zimmer Biomet were worth $18,407,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ZBH. Ameriprise Financial Inc. lifted its stake in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Zimmer Biomet by 251.3% during the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Nuveen LLC bought a new stake in Zimmer Biomet in the 1st quarter worth approximately $155,891,000. Alyeska Investment Group L.P. bought a new stake in Zimmer Biomet in the 1st quarter worth approximately $101,294,000. Finally, Dodge & Cox boosted its stake in Zimmer Biomet by 2.3% in the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after buying an additional 446,018 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZBH shares. Royal Bank Of Canada set a $111.00 price target on shares of Zimmer Biomet in a research note on Friday, October 10th. BTIG Research increased their target price on shares of Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a report on Monday, October 13th. Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price on the stock. Raymond James Financial upped their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $111.94.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Up 1.2%

Shares of NYSE ZBH opened at $100.77 on Monday. The firm’s fifty day moving average is $101.45 and its 200 day moving average is $97.62. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market cap of $19.96 billion, a price-to-earnings ratio of 24.52, a PEG ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the firm earned $2.01 EPS. The company’s revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.